Efficacy & Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis & Early Stage Acute Liver Failure
|ClinicalTrials.gov Identifier: NCT01318525|
Recruitment Status : Unknown
Verified April 2011 by Alfact Innovation.
Recruitment status was: Recruiting
First Posted : March 18, 2011
Last Update Posted : April 5, 2011
Information provided by:
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||May 2012|
|Estimated Study Completion Date :||September 2012|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Nalpas B, Ichaï P, Jamot L, Carbonell N, Rudler M, Mathurin P, Durand F, Gerken G, Manns M, Trautwein C, Larrey D, Radenne S, Duvoux C, Leroy V, Bernuau J, Faivre J, Moniaux N, Bréchot C, Amouyal G, Amouyal P, Samuel D. A Proof of Concept, Phase II Randomized European Trial, on the Efficacy of ALF-5755, a Novel Extracellular Matrix-Targeted Antioxidant in Patients with Acute Liver Diseases. PLoS One. 2016 Mar 16;11(3):e0150733. doi: 10.1371/journal.pone.0150733. eCollection 2016.